GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
- Successful completion of Level 2 App integration with Dexcom's Developer Program
- Development of predictive algorithm with 95% accuracy for hypoglycemia detection
- Partnership with UC Irvine's MADO program through CALIT2
- Expected full mobile device functionality by mid-June 2025
- Access to Dexcom's API for CGM data integration
- None.
Del Mar, California--(Newsfile Corp. - May 27, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a).
The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and integrate Dexcom CGM data into their own applications. Dexcom partners with the company to gain access to app credentials, sand box data, and development support. The Dexcom API allows partners to integrate DEXCOM CGM Data, such as glucose levels, into their applications.
It is expected that in mid-June the next level of App integration development will be approved resulting in a fully functional back-end to front-end completion where the app will run on a mobile device.
Developments Include:
- A functional front-end and back-end App capable of running on an emulator.
- A trained predictive algorithm for detecting hypoglycemia episodes with
95% accuracy. - Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data.
GlucoGuard is also developing a suite of AI features designed to predict negative blood glucose events and mitigate these events before the patient suffers catastrophic adverse effects. The ability to manage glucose in this manner is a groundbreaking advancement that will truly establish GlucoGuard as a revolutionary technology in the field of diabetes – a multibillion-dollar industry.
"We are very appreciative to all our partners in reaching these milestones," commented ADHC. "Developments are progressing rapidly and the GlucoGuard team is very grateful for the amazing support from all of our stakeholders."
ABOUT GLUCOGUARD
GlucoGuard
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_001full.jpg
ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
ABOUT ARETE BIOSCIENCES, Inc.
Arete
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_002full.jpg
Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space.
Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries.
ABOUT UCI CALIT 2
UCI CALIT2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_003full.jpg
Created in 2000, the California Institute for Telecommunications and Information Technology – known as CALIT2 – is one of four Gray Davis Institutes for Science and Innovation located on University of California campuses. The founding objective of CALIT2 was to create a world-class multidisciplinary research institute to promote discovery and innovation, notably to harness the ubiquity and scale of the internet and wireless technologies to accelerate growth in many different scientific areas and industries that are undergoing a massive transformation. Over two decades, CALIT2 has focused on transdisciplinary approaches of significant scale and complexity, as well as the creation of new, advanced scientific facilities, technical staff opportunities, and centers and 'living laboratories' to attract and support the nearly 250 UCI faculty who have opted to affiliate with the institute
ABOUT DEXCOM
Dexcom
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_004full.jpg
Dexcom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
COMPANY OVERVIEW
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
- A leading U.S. research university, UNIVERSITY OF CALIFORNIA IRVINE.
- A highly respected biomedical engineering firm, ARETE BIOSCIENCE.
- A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector DEXCOM.
Further details on these collaborations will be disclosed soon.
CUTTING-EDGE TECHNOLOGY FOR UNMET MEDICAL NEEDS
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
ABOUT ARTIFICIAL INTELLIGENCE AND HEALTHCARE
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
- Improving outcomes for both patients and clinical teams
- Lowering healthcare costs
- Benefitting population health
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45-minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.
ABOUT THE DIABETES MARKET
The diabetes market is poised for substantial growth, with the U.S. market valued at
For more information on the
The Continuous Glucose Monitoring (CGM) sector, valued at
For details on the CGM market, visit: Continuous Glucose Monitoring Market.
Image 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_005full.jpg
ABOUT GLUCOGUARD
GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
Image 2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/253262_8ece25821499ca16_006full.jpg
ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
INVESTOR HOTLINE 858-325-7098
Email: JC@American-Diversified.com ADHCInvestor@yahoo.com
SOCIAL MEDIA
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253262
FAQ
What milestone has ADHC's GlucoGuard achieved in May 2025?
What is the accuracy rate of GlucoGuard's predictive algorithm for hypoglycemia?
When will ADHC's GlucoGuard app be fully functional on mobile devices?
Who is GlucoGuard partnering with for app development?
What is the purpose of GlucoGuard's AI features?
